Efficacy and Safety of Flumatinib for Maintenance Therapy in Ph-Positive B-Cell Acute Lymphocytic Leukemia Patients with Insensitivity or Intolerance to Dasatinib after Allogeneic Hematopoietic Stem Cell Transplantation: Two Case Reports
-
Graphical Abstract
-
Abstract
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) presents a potential remedy for Philadelphia chromosome-positive (Ph-positive) B-cell acute lymphoblastic leukemia (B-ALL). A tyrosine kinase inhibitor (TKI), such as dasatinib, may decrease the incidence of leukemic relapse during post-transplantation maintenance therapy. However, resistance or intolerance to TKIs remains a major challenge. The paper presented the clinical data of two patients with Ph-positive B-ALL who were treated with flumatinib after allo-HSCT. This case report aims to evaluate the safety and efficacy of flumatinib, a selective BCR/ABL inhibitor, in treating Ph-positive B-ALL patients who show resistance or intolerance to dasatinib after allo-HSCT. The two Ph-positive B-ALL patients treated with flumatinib following allo-HSCT tolerated the medication well and achieved sustained molecular remission. The paper suggests that flumatinib exhibit significant efficacy and safety in patients with Ph-positive B-ALL who underwent allo-HSCT, which deserves additional investigation.
-
-